Development of a CE‐MS method for the study of riociguat and metabolite M1 in pharmaceutical analysis

Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and reso...

Full description

Saved in:
Bibliographic Details
Published inElectrophoresis Vol. 40; no. 22; pp. 2936 - 2945
Main Authors Štícha, Martin, Hložek, Tomáš, Bursová, Miroslava, Čabala, Radomír, Jelínek, Ivan
Format Journal Article
LanguageEnglish
Published Germany Wiley Subscription Services, Inc 01.11.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60–5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH, were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02.
AbstractList Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60-5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pK , were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pK = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pK = 4.40 ± 0.02.
Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60–5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH, were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02.
Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60-5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH , were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02.Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60-5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH , were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02.
Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60–5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH, were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02.
Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60–5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, p K BH , were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pK BH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pK BH = 4.40 ± 0.02.
Author Bursová, Miroslava
Čabala, Radomír
Jelínek, Ivan
Štícha, Martin
Hložek, Tomáš
Author_xml – sequence: 1
  givenname: Martin
  orcidid: 0000-0001-8008-7668
  surname: Štícha
  fullname: Štícha, Martin
  organization: Charles University
– sequence: 2
  givenname: Tomáš
  surname: Hložek
  fullname: Hložek, Tomáš
  organization: Charles University and General University Hospital in Prague
– sequence: 3
  givenname: Miroslava
  surname: Bursová
  fullname: Bursová, Miroslava
  organization: Charles University and General University Hospital in Prague
– sequence: 4
  givenname: Radomír
  orcidid: 0000-0001-7022-1317
  surname: Čabala
  fullname: Čabala, Radomír
  organization: Charles University and General University Hospital in Prague
– sequence: 5
  givenname: Ivan
  surname: Jelínek
  fullname: Jelínek, Ivan
  email: ivan.jelinek@natur.cuni.cz
  organization: Charles University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31520473$$D View this record in MEDLINE/PubMed
BookMark eNqF0ctu1DAUBmALFdHpwJYlssSGzQzHt0m8RMNwkaYCqbCOHOek48qJg-2AZscj8Iw8CUlbuuhmvPHm-8-R_V-Qsz70SMhLBmsGwN-iH9KaA9MArGRPyIIpzld8U4ozsgBWiBWUQp2Ti5RuAEBqKZ-RczEpkIVYkOv3-BN9GDrsMw0tNXS7-_v7z-UV7TAfQkPbEGk-IE15bI6ziC5Ydz2aTE3fzMrUwbuM9JJR19PhYGJnLI7ZWeMnY_wxufScPG2NT_ji_l6S7x9237afVvsvHz9v3-1XVooSVsikLpTEmhnTcq1QNqIRViCUm6IWrGy4LRioumFaiemwuq0NM7zVLbeGiyV5czd3iOHHiClXnUsWvTc9hjFVXAjFeKk36jTlGjTc7lmS14_oTRjj9LTbgazQslDz7lf3aqw7bKohus7EY_X_tyewvgM2hpQitg-EQTXXWc11Vg91TgH5KGBdNtmFPkfj_MnYL-fxeGJJtdt_vSpAgfgH2emyvg
CitedBy_id crossref_primary_10_1002_elps_202000135
crossref_primary_10_1016_j_jpba_2022_115059
crossref_primary_10_1016_j_electacta_2024_144823
Cites_doi 10.1002/elps.201600058
10.1016/j.jchromb.2006.03.015
10.2147/DDDT.S117277
10.1002/elps.200500260
10.1016/j.chroma.2004.02.087
10.1107/S2052520617006011
10.1007/s00508-016-1068-8
10.1002/elps.200405982
10.1007/s00216-010-3741-5
10.1002/phar.1592
10.1007/s40265-013-0149-5
10.1007/s40262-017-0604-7
10.1002/rcm.4458
10.4155/bio.14.257
10.1007/s13361-010-0037-0
10.1007/s40265-014-0317-2
10.5582/bst.2018.01081
10.1016/j.aca.2013.01.061
ContentType Journal Article
Copyright 2019 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Copyright_xml – notice: 2019 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
– notice: 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7U5
8FD
L7M
7X8
7S9
L.6
DOI 10.1002/elps.201900181
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Solid State and Superconductivity Abstracts
Technology Research Database
Advanced Technologies Database with Aerospace
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Technology Research Database
Advanced Technologies Database with Aerospace
Solid State and Superconductivity Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList MEDLINE
Technology Research Database
AGRICOLA
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1522-2683
EndPage 2945
ExternalDocumentID 31520473
10_1002_elps_201900181
ELPS7050
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Ministry of Education, Youth and Sports
  funderid: CZ.02.1.01/0.0/0.0/15_003/0000417
– fundername: Ministry of Education, Youth and Sports
  grantid: CZ.02.1.01/0.0/0.0/15_003/0000417
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHBH
AAHHS
AAHQN
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACPOU
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AI.
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AQPKS
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LH5
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P4D
PALCI
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
RNS
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
UB1
V2E
VH1
W8V
W99
WBKPD
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WRJ
WXSBR
WYISQ
XG1
XPP
XV2
Y6R
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7U5
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
L7M
7X8
7S9
L.6
ID FETCH-LOGICAL-c4380-e149754eb1aaf295e4d3d3c3e0867b318d2c7105bd19533331bfba1a2f9f2ca23
IEDL.DBID DR2
ISSN 0173-0835
1522-2683
IngestDate Fri Jul 11 18:26:43 EDT 2025
Fri Jul 11 06:39:38 EDT 2025
Fri Jul 25 06:07:42 EDT 2025
Wed Feb 19 02:30:50 EST 2025
Tue Jul 01 04:03:09 EDT 2025
Thu Apr 24 22:54:57 EDT 2025
Wed Jan 22 16:37:15 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 22
Keywords Dissociation constant
Capillary electrophoresis
Mass spectrometry
Riociguat
Fragmentation
Language English
License 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4380-e149754eb1aaf295e4d3d3c3e0867b318d2c7105bd19533331bfba1a2f9f2ca23
Notes See article online to view Fig. 5 in color.
Color online
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-7022-1317
0000-0001-8008-7668
PMID 31520473
PQID 2331794752
PQPubID 2045162
PageCount 10
ParticipantIDs proquest_miscellaneous_2335128965
proquest_miscellaneous_2290901953
proquest_journals_2331794752
pubmed_primary_31520473
crossref_primary_10_1002_elps_201900181
crossref_citationtrail_10_1002_elps_201900181
wiley_primary_10_1002_elps_201900181_ELPS7050
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2019
PublicationDateYYYYMMDD 2019-11-01
PublicationDate_xml – month: 11
  year: 2019
  text: November 2019
PublicationDecade 2010
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Weinheim
PublicationTitle Electrophoresis
PublicationTitleAlternate Electrophoresis
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2015; 35
2017; 73
2010; 24
2010
2013; 73
2017; 11
2004; 25
2010; 398
2011; 22
2013; 773
2016; 128
2016
2014; 74
2018; 12
2005; 26
2018; 11
2006; 841
2015; 7
2016; 37
2004; 1037
2018; 57
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_14_1
Frisch M. J. (e_1_2_7_16_1) 2016
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_23_1
e_1_2_7_11_1
e_1_2_7_22_1
e_1_2_7_10_1
e_1_2_7_20_1
Zhang J. (e_1_2_7_8_1) 2018; 11
Lewars E. G. (e_1_2_7_21_1) 2010
References_xml – volume: 11
  start-page: 1195
  year: 2017
  end-page: 1207
  publication-title: Drug Des. Devel. Ther.
– volume: 11
  start-page: 423
  year: 2018
  end-page: 430
  publication-title: J. Clin. Exp. Med.
– volume: 128
  start-page: 882
  year: 2016
  end-page: 889
  publication-title: Wien. Klin. Wochenschr.
– volume: 37
  start-page: 1591
  year: 2016
  end-page: 1608
  publication-title: Electrophoresis
– volume: 73
  start-page: 891
  year: 2017
  end-page: 898
  publication-title: Acta Cryst. Bs
– volume: 74
  start-page: 2065
  year: 2014
  end-page: 2078
  publication-title: Drugs
– volume: 841
  start-page: 129
  year: 2006
  end-page: 134
  publication-title: J. Chromatogr. B
– volume: 398
  start-page: 29
  year: 2010
  end-page: 52
  publication-title: Anal Bioanal. Chem.
– volume: 773
  start-page: 24
  year: 2013
  end-page: 36
  publication-title: Anal. Chim. Acta
– volume: 1037
  start-page: 445
  year: 2004
  publication-title: J. Chromatogr. A
– volume: 24
  start-page: 1025
  year: 2010
  end-page: 1031
  publication-title: Rapid Commun. Mass Spectrom.
– volume: 35
  start-page: 502
  year: 2015
  end-page: 519
  publication-title: Pharmacotherapy
– volume: 57
  start-page: 647
  year: 2018
  end-page: 661
  publication-title: Clin. Pharmacokinet.
– year: 2016
– volume: 12
  start-page: 369
  year: 2018
  end-page: 374
  publication-title: BioSci. Trends
– volume: 25
  start-page: 3080
  year: 2004
  end-page: 3085
  publication-title: Electrophoresis
– volume: 7
  start-page: 193
  year: 2015
  end-page: 205
  publication-title: Bioanalysis
– volume: 22
  start-page: 360
  year: 2011
  end-page: 368
  publication-title: J. Am. Soc. Mass Spectrom.
– volume: 73
  start-page: 1967
  year: 2013
  end-page: 1975
  publication-title: Drugs
– volume: 26
  start-page: 3221
  year: 2005
  end-page: 3231
  publication-title: Electrophoresis
– year: 2010
– ident: e_1_2_7_15_1
  doi: 10.1002/elps.201600058
– ident: e_1_2_7_20_1
  doi: 10.1016/j.jchromb.2006.03.015
– ident: e_1_2_7_6_1
  doi: 10.2147/DDDT.S117277
– ident: e_1_2_7_19_1
  doi: 10.1002/elps.200500260
– ident: e_1_2_7_2_1
– ident: e_1_2_7_18_1
  doi: 10.1016/j.chroma.2004.02.087
– ident: e_1_2_7_11_1
  doi: 10.1107/S2052520617006011
– ident: e_1_2_7_10_1
  doi: 10.1007/s00508-016-1068-8
– ident: e_1_2_7_17_1
  doi: 10.1002/elps.200405982
– volume-title: Gaussian 16
  year: 2016
  ident: e_1_2_7_16_1
– volume-title: Computational Chemistry: Introduction to the Theory and Applications of Molecular and Quantum Mechanics
  year: 2010
  ident: e_1_2_7_21_1
– volume: 11
  start-page: 423
  year: 2018
  ident: e_1_2_7_8_1
  publication-title: J. Clin. Exp. Med.
– ident: e_1_2_7_13_1
  doi: 10.1007/s00216-010-3741-5
– ident: e_1_2_7_5_1
  doi: 10.1002/phar.1592
– ident: e_1_2_7_3_1
  doi: 10.1007/s40265-013-0149-5
– ident: e_1_2_7_7_1
  doi: 10.1007/s40262-017-0604-7
– ident: e_1_2_7_22_1
  doi: 10.1002/rcm.4458
– ident: e_1_2_7_9_1
  doi: 10.4155/bio.14.257
– ident: e_1_2_7_23_1
  doi: 10.1007/s13361-010-0037-0
– ident: e_1_2_7_4_1
  doi: 10.1007/s40265-014-0317-2
– ident: e_1_2_7_12_1
  doi: 10.5582/bst.2018.01081
– ident: e_1_2_7_14_1
  doi: 10.1016/j.aca.2013.01.061
SSID ssj0004944
Score 2.3123815
Snippet Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2936
SubjectTerms antihypertensive agents
buffers
calibration
Capillary electrophoresis
dissociation
Dissociation constant
Electrolytes
Electrophoresis, Capillary - methods
formates
Fragmentation
Humans
Hypertension
ionic strength
Ions
Limit of Detection
Linear Models
Lithium
lithium acetate
Mass spectrometry
Mass Spectrometry - methods
Metabolites
Parameter estimation
Photometry
Pyrazoles - analysis
Pyrazoles - blood
Pyrazoles - chemistry
Pyrazoles - metabolism
Pyrimidines - analysis
Pyrimidines - blood
Pyrimidines - chemistry
Pyrimidines - metabolism
Reproducibility of Results
Riociguat
Spectrometry
Symmetry
Title Development of a CE‐MS method for the study of riociguat and metabolite M1 in pharmaceutical analysis
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Felps.201900181
https://www.ncbi.nlm.nih.gov/pubmed/31520473
https://www.proquest.com/docview/2331794752
https://www.proquest.com/docview/2290901953
https://www.proquest.com/docview/2335128965
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LTxsxELYqLu2ltLSFtBS5ElJPho0f8fpYRUEIkariIXFb-bWAQJsIkgsnfkJ_I7-EmXV2SagKQuxxPV557Znx58d8Q8hm7DrvtfDMeemZzG1gubKOBW58NEaHWLPtD3_3do_l3ok6mYviT_wQ7YYbWkbtr9HArbvefiANjZdjpNuGCQ05p8AJ44UtREUHD_xR0shE7q0F0jCrhrUx49uL1RdnpX-g5iJyraeenWVim0anGycXW9OJ2_I3j_gcX_NXH8j7GS6lv5IifSRvYrVC3vabdHCfyOnc9SI6Kqml_cHd7d_hIU1JqCmgXwpoktaEtShxdQ4Dfzq1E2qrgFKgbxjxTIddel7R8dn8bjrIJHaUz-R4Z3DU32WzLA3MI1s9i7DG0kqCz7e25EZFGUQQXkRYLGkHLiNwDzBGuYAndvB0Xels1_LSlNxbLr6QpWpUxTVCbdClznId856XUJ4747yBj5Qqj6A0HcKaUSr8jMIcM2lcFol8mRfYfUXbfR3ys5UfJ_KO_0quN4NezIwYSqGt4K604h3yoy2GbsczFVvF0RRkuMkMBl2KJ2SEAFiVm57qkNWkUG1zBOCnTGqozWq1eKadxWD_z6HOVPb1hfLfyDt8maIo18nS5GoavwOcmriN2mTuAeIKGU0
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1Z3NbhMxEMdHVTmUC98fKQWMBOLkduNdx-sDB5SmSmlSIdpKvS2211sqqk3UJkJw4hF4FV6FR-BJmFnvbhsQIA49kKsnkWPPjP-7tn8D8NR3rXMqdty6xPEkNTlPpbE8F9p5rVXuK9r-eLc3PEheHcrDJfja3IUJfIj2hRtFRpWvKcDphfTGOTXUn0yJt40rGkGn6nOVO_7jB3xqO3uxvYlT_EyIrcF-f8jrwgLcEWCde3wsUDLBNGVMIbT0SR7nsYs96ntl0ctz4XDllTanTSb8dG1hTdeIQhfCGWIdYNa_QmXECde_-eacWJXoJODEVUzgZ9lwIiOxsdjfxXXwF3G7qJWrxW7rOnxrhimccXm_Pp_ZdffpJ4LkfzWON-BaLb3ZyxArN2HJl7dgpd9UvLsNRxdOULFJwQzrD75__jLeY6HONkOBz1Aws4rJSxanx-jbR3MzY6bMyQpDii51s3GXHZds-u7ihgHaBADMHTi4lP95F5bLSenvAzO5KlSUKp_2XILtqdXWafyRQqYe46IDvHGLzNWUdioWcpIFvrTIaLqydro68Ly1nwY-yW8t1xovy-o8ha3YV8zISooOPGmbcdhp28iUfjJHG6EjTfdK4z_YxDEqx1T3ZAfuBQ9uuxOjRIwShd_mlR_-pZ_ZYPR6T0UyWv1H-8ewMtwfj7LR9u7OA7hKBuHS6Bosz07n_iGqx5l9VMUrg7eX7dg_AC4mdsw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1Z3NbhMxEMdHVZGAC98fgQJGAnFyu_Ha8frAAeVDLW2qilKpt8VfW6pWm6hNhODEI_AovAqvwJMwXu9uGxAgDj2QqyeR154Z_ze2fwPwzHeNtTK11FhuKc-0o5nQhjqmrFdKOl_R9sfbvfU9_npf7C_B1-YuTORDtH-4hcio8nUI8Kkr1s6gof54GnDbuKAF5lR9rHLTf_yAL22nLzcGOMPPGRsN3_bXaV1XgNrAV6ce3wqk4JiltC6YEp671KU29SjvpUEnd8ziwiuMC3tM-OmawuiuZoUqmNUBdYBJ_xLvJSoUixi8OQNWccUjTVymgfssGkxkwtYW-7u4DP6ibRelcrXWja7Dt2aU4hGXo9X5zKzaTz8BJP-nYbwB12rhTV7FSLkJS768BVf6Tb2723Bw7vwUmRREk_7w--cv410Sq2wTlPcE5TKpiLzB4uQQPftgrmdEly5YYUCFK91k3CWHJZm-P79dgDYR_3IH9i7kOe_Ccjkp_X0g2slCJpn0Wc9ybM-MMlbhjxQi8xgVHaCNV-S2ZrSHUiHHeaRLszxMV95OVwdetPbTSCf5reVK42R5naWwFfuK-VgK1oGnbTMOe9g00qWfzNGGKXTz8GR_sElT1I2Z6okO3IsO3HYnRYGYcInfppUb_qWf-XBrZ1cmInnwj_ZP4PLOYJRvbWxvPoSroT3eGF2B5dnJ3D9C6Tgzj6toJfDuov36BzmkdXs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+CE%E2%80%90MS+method+for+the+study+of+riociguat+and+metabolite+M1+in+pharmaceutical+analysis&rft.jtitle=Electrophoresis&rft.au=%C5%A0t%C3%ADcha%2C+Martin&rft.au=Hlo%C5%BEek%2C+Tom%C3%A1%C5%A1&rft.au=Bursov%C3%A1%2C+Miroslava&rft.au=%C4%8Cabala%2C+Radom%C3%ADr&rft.date=2019-11-01&rft.issn=0173-0835&rft.eissn=1522-2683&rft.volume=40&rft.issue=22&rft.spage=2936&rft.epage=2945&rft_id=info:doi/10.1002%2Felps.201900181&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_elps_201900181
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0173-0835&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0173-0835&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0173-0835&client=summon